MA50013B1 - Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton - Google Patents
Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de brutonInfo
- Publication number
- MA50013B1 MA50013B1 MA50013A MA50013A MA50013B1 MA 50013 B1 MA50013 B1 MA 50013B1 MA 50013 A MA50013 A MA 50013A MA 50013 A MA50013 A MA 50013A MA 50013 B1 MA50013 B1 MA 50013B1
- Authority
- MA
- Morocco
- Prior art keywords
- bruton
- benzoazepine
- analogs
- tyrosine kinase
- kinase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
L'invention concerne des composés de formule (i), ou des sels pharmaceutiquement acceptables de ceux-ci, et leurs procédés de production ainsi que leur utilisation dans le traitement d'une maladie sensible à l'inhibition de la tyrosine de bruton.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762485745P | 2017-04-14 | 2017-04-14 | |
| PCT/US2018/027415 WO2018191577A1 (fr) | 2017-04-14 | 2018-04-13 | Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA50013A MA50013A (fr) | 2020-07-08 |
| MA50013B1 true MA50013B1 (fr) | 2024-05-31 |
Family
ID=62092333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA50013A MA50013B1 (fr) | 2017-04-14 | 2018-04-13 | Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton |
Country Status (36)
| Country | Link |
|---|---|
| US (5) | US10227341B2 (fr) |
| EP (2) | EP4249071A3 (fr) |
| JP (3) | JP7145874B2 (fr) |
| KR (3) | KR20250140646A (fr) |
| CN (2) | CN117567453A (fr) |
| AR (2) | AR111594A1 (fr) |
| AU (3) | AU2018253209B2 (fr) |
| CA (1) | CA3058774A1 (fr) |
| CL (1) | CL2019002900A1 (fr) |
| CO (1) | CO2019012571A2 (fr) |
| CR (2) | CR20190517A (fr) |
| DK (1) | DK3609886T3 (fr) |
| EA (1) | EA201992354A1 (fr) |
| ES (1) | ES2975769T3 (fr) |
| FI (1) | FI3609886T3 (fr) |
| HR (1) | HRP20240361T1 (fr) |
| HU (1) | HUE066253T2 (fr) |
| IL (3) | IL269933B (fr) |
| JO (1) | JOP20190233B1 (fr) |
| LT (1) | LT3609886T (fr) |
| MA (1) | MA50013B1 (fr) |
| MD (1) | MD3609886T2 (fr) |
| MX (1) | MX2023000812A (fr) |
| PE (2) | PE20240930A1 (fr) |
| PH (1) | PH12019502334A1 (fr) |
| PL (1) | PL3609886T3 (fr) |
| PT (1) | PT3609886T (fr) |
| RS (1) | RS65386B1 (fr) |
| SA (1) | SA519410292B1 (fr) |
| SG (1) | SG11201909224QA (fr) |
| SI (1) | SI3609886T1 (fr) |
| SM (1) | SMT202400166T1 (fr) |
| TW (2) | TWI846229B (fr) |
| UA (1) | UA127347C2 (fr) |
| WO (1) | WO2018191577A1 (fr) |
| ZA (1) | ZA202306172B (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20181109T1 (hr) | 2013-12-11 | 2018-11-02 | Biogen Ma Inc. | Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji |
| RS65386B1 (sr) | 2017-04-14 | 2024-04-30 | Biogen Ma Inc | Benzoazepinski analozi kao sredstva za inhibiciju brutonove tirozin kinaze |
| US11820760B2 (en) | 2018-10-15 | 2023-11-21 | Biogen Ma Inc. | Crystalline polymorphs of Bruton's tyrosine kinase inhibitors |
| JP7747523B2 (ja) * | 2019-05-15 | 2025-10-01 | バイオジェン・エムエイ・インコーポレイテッド | ブルトン型チロシンキナーゼの阻害剤 |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| US20240216330A1 (en) * | 2021-04-02 | 2024-07-04 | Biogen Ma Inc. | Combination treatment methods of multiple sclerosis |
| WO2023086521A1 (fr) | 2021-11-10 | 2023-05-19 | Biogen Ma Inc. | Inhibiteurs de btk |
| CA3240051A1 (fr) | 2021-12-30 | 2023-07-06 | Beigene Switzerland Gmbh | Degradation de la tyrosine kinase de bruton (btk) par conjugaison d'inhibiteurs de btk avec un ligand de ligase e3 et procedes d'utilisation |
| JP7805983B2 (ja) | 2022-03-22 | 2026-01-26 | アッヴィ・インコーポレイテッド | ブルトン型チロシンキナーゼを分解するためのピリミジン |
| WO2024245578A1 (fr) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Combinaisons thérapeutiques d'un inhibiteur de btk irréversible et d'un inhibiteur de btk réversible macrocyclique |
| WO2024245577A1 (fr) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Combinaisons thérapeutiques d'un inhibiteur irréversible de btk et d'un inhibiteur réversible de btk |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| WO2008116064A2 (fr) | 2007-03-21 | 2008-09-25 | Bristol-Myers Squibb Company | Composés hétérocycliques fusionnés utiles en tant que modulateurs de kinases |
| ES2406129T3 (es) | 2007-10-05 | 2013-06-05 | Verastem, Inc. | Derivados de purina sustituidos con pirimidina |
| JPWO2009107391A1 (ja) | 2008-02-27 | 2011-06-30 | 武田薬品工業株式会社 | ６員芳香環含有化合物 |
| AU2009262068C1 (en) | 2008-06-27 | 2015-07-02 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| TWI557127B (zh) * | 2009-09-04 | 2016-11-11 | 百健Ｍａ公司 | 布魯頓氏酪胺酸激酶抑制劑 |
| US8334292B1 (en) | 2010-06-14 | 2012-12-18 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
| CN103889987B (zh) | 2011-07-19 | 2016-09-14 | 默沙东有限责任公司 | 作为btk抑制剂的选择的咪唑并吡嗪类 |
| TWI648274B (zh) * | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| US20140357636A1 (en) | 2013-02-21 | 2014-12-04 | Wayne Rothbaum | Treatment of Skeletal-Related Disorders |
| US10329270B2 (en) | 2013-10-21 | 2019-06-25 | Merck Patent Gmbh | Heteroaryl compounds as BTK inhibitors and uses thereof |
| HRP20181109T1 (hr) | 2013-12-11 | 2018-11-02 | Biogen Ma Inc. | Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji |
| CN107001362A (zh) | 2014-10-06 | 2017-08-01 | 默克专利有限公司 | 用作btk抑制剂的杂芳基化合物及其用途 |
| RS65386B1 (sr) | 2017-04-14 | 2024-04-30 | Biogen Ma Inc | Benzoazepinski analozi kao sredstva za inhibiciju brutonove tirozin kinaze |
-
2018
- 2018-04-13 RS RS20240419A patent/RS65386B1/sr unknown
- 2018-04-13 EA EA201992354A patent/EA201992354A1/ru unknown
- 2018-04-13 CR CR20190517A patent/CR20190517A/es unknown
- 2018-04-13 SM SM20240166T patent/SMT202400166T1/it unknown
- 2018-04-13 TW TW111149550A patent/TWI846229B/zh active
- 2018-04-13 IL IL269933A patent/IL269933B/en unknown
- 2018-04-13 DK DK18721632.0T patent/DK3609886T3/da active
- 2018-04-13 SG SG11201909224Q patent/SG11201909224QA/en unknown
- 2018-04-13 FI FIEP18721632.0T patent/FI3609886T3/fi active
- 2018-04-13 CN CN202311088635.7A patent/CN117567453A/zh active Pending
- 2018-04-13 JP JP2019555961A patent/JP7145874B2/ja active Active
- 2018-04-13 AU AU2018253209A patent/AU2018253209B2/en active Active
- 2018-04-13 CA CA3058774A patent/CA3058774A1/fr active Pending
- 2018-04-13 LT LTEPPCT/US2018/027415T patent/LT3609886T/lt unknown
- 2018-04-13 WO PCT/US2018/027415 patent/WO2018191577A1/fr not_active Ceased
- 2018-04-13 KR KR1020257031163A patent/KR20250140646A/ko active Pending
- 2018-04-13 PE PE2024000228A patent/PE20240930A1/es unknown
- 2018-04-13 MA MA50013A patent/MA50013B1/fr unknown
- 2018-04-13 HR HRP20240361TT patent/HRP20240361T1/hr unknown
- 2018-04-13 AR ARP180100935A patent/AR111594A1/es not_active Application Discontinuation
- 2018-04-13 TW TW107112785A patent/TWI790227B/zh active
- 2018-04-13 UA UAA201911128A patent/UA127347C2/uk unknown
- 2018-04-13 US US15/952,505 patent/US10227341B2/en active Active
- 2018-04-13 PL PL18721632.0T patent/PL3609886T3/pl unknown
- 2018-04-13 IL IL316713A patent/IL316713A/en unknown
- 2018-04-13 EP EP23187919.8A patent/EP4249071A3/fr active Pending
- 2018-04-13 PE PE2019002016A patent/PE20200740A1/es unknown
- 2018-04-13 CN CN201880031744.6A patent/CN110621670B/zh active Active
- 2018-04-13 HU HUE18721632A patent/HUE066253T2/hu unknown
- 2018-04-13 ES ES18721632T patent/ES2975769T3/es active Active
- 2018-04-13 JO JOJO/P/2019/0233A patent/JOP20190233B1/ar active
- 2018-04-13 EP EP18721632.0A patent/EP3609886B1/fr active Active
- 2018-04-13 SI SI201831083T patent/SI3609886T1/sl unknown
- 2018-04-13 PT PT187216320T patent/PT3609886T/pt unknown
- 2018-04-13 KR KR1020237040706A patent/KR102862996B1/ko active Active
- 2018-04-13 MD MDE20200193T patent/MD3609886T2/ro unknown
- 2018-04-13 KR KR1020197032715A patent/KR102607900B1/ko active Active
- 2018-04-13 IL IL294175A patent/IL294175B2/en unknown
- 2018-08-27 US US16/113,455 patent/US10189829B2/en active Active
-
2019
- 2019-04-13 CR CR20230539A patent/CR20230539A/es unknown
- 2019-08-07 US US16/534,540 patent/US10961237B2/en active Active
- 2019-10-10 SA SA519410292A patent/SA519410292B1/ar unknown
- 2019-10-11 MX MX2023000812A patent/MX2023000812A/es unknown
- 2019-10-11 CL CL2019002900A patent/CL2019002900A1/es unknown
- 2019-10-14 PH PH12019502334A patent/PH12019502334A1/en unknown
- 2019-11-12 CO CONC2019/0012571A patent/CO2019012571A2/es unknown
-
2021
- 2021-02-24 US US17/183,702 patent/US11427577B2/en active Active
-
2022
- 2022-07-22 US US17/871,157 patent/US11858926B2/en active Active
- 2022-08-18 AU AU2022218560A patent/AU2022218560B2/en active Active
- 2022-09-20 JP JP2022148866A patent/JP7581294B2/ja active Active
-
2023
- 2023-06-12 ZA ZA2023/06172A patent/ZA202306172B/en unknown
- 2023-06-15 AR ARP230101541A patent/AR129632A2/es unknown
-
2024
- 2024-06-20 AU AU2024204241A patent/AU2024204241A1/en active Pending
- 2024-10-30 JP JP2024190472A patent/JP7778206B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
| MA47079A (fr) | Composés amino-triazolopyidines et leur utilisation pour traiter le cancer | |
| MA44674A (fr) | Inhibiteurs de bromodomaine | |
| MA38661A1 (fr) | Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine | |
| MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA54386B1 (fr) | Modulateurs de trex1 | |
| MA37834A1 (fr) | Analogues de pyridazine 1,4-disubstituée et procédés de traitement de troubles liés à une déficience en smn | |
| MA40225A (fr) | Composés dihydroisoquinolinone substitués | |
| PH12019502334A1 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| MA47043A1 (fr) | Composés indole carboxamides utiles comme inhibiteurs de kinase | |
| MA34837B1 (fr) | Composés indoliques ou analogues de ceux-ci utiles dans le traitement de la dégénérescence maculaire liée à l'âge (dmla) | |
| MA40955B1 (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
| EA202191955A1 (ru) | Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы | |
| MA41633B1 (fr) | Composés amide en tant qu'agonistes du récepteur 5-ht4 | |
| MA43294A1 (fr) | Sels et promédicaments de 1-méthyl -d-tryptophane | |
| MA43913A (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
| MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
| MA38009A1 (fr) | Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer | |
| MA39926B1 (fr) | Dérivés de dihétérocycle liés à cycloalkyle | |
| MA53372B1 (fr) | Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine | |
| MA39448B1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
| MA39533A1 (fr) | Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives | |
| MA44383B1 (fr) | Un derivé de 4-(3-pyrazolylamino)-benzimidazole en tant qu'inhibiteur de jak1 pour le traitement du cancer | |
| FR3058640B1 (fr) | Composes pour leur utilisation dans le traitement de la grippe | |
| MA44503B1 (fr) | Composés de pyrrolotriazine en tant qu'inhibiteurs de tam |